CliniGenetics announces promising pre-clinical results

CliniGenetics, from Nimes, France, a biopharmaceutical company that identifies and develops new targets and products for the treatment of cardiovascular diseases, has announced a successful pre-clinical results for Nimoxine, an optimised molecule that fights atherothrombotic disease.

Cholesterol levels in mice treated with Nimoxine dropped immediately, atheroma plaque showed signs of regression and weight gain slowed down. The pre-clinical trials were conducted blindly by an independent laboratory, in accordance with Good Laboratory Practice (GLP) standards.

Nimoxine belongs to a family of molecules identified and optimised by CliniGenetics for their ability to considerably reduce cholesterol and triglyceride levels. This molecule can be used to block the accumulation of lipids and macrophages that are central to the growth of vascular lesions in atherothrombosis. Nimoxine is a novel therapeutic approach to treating atherothrombotic disease, directly targeting atheroma plaque to slow down its growth and avoid the complications linked to it, including thrombosis and cerebrovascular attack.

'The excellent results obtained from these pre-clinical trials endorse our approach to finding valid treatments for atherothrombotic disease,' said Dr Gerard Marguerie, vice president and chief scientific officer of CliniGenetics.